CDK7 Inhibitors

About 1cBio

1cBio is a private, preclinical-to-clinical stage biopharmaceutical company leveraging a rational discovery platform to convert transformative scientific ideas into future medicines. Its strategy centers on defined, clinically validated mechanisms of action, aiming to treat disease while preempting resistance. The company's pipeline includes a partnered Phase 1/2a program for hypophosphatasia and a potentially best-in-class, selective PARP1 inhibitor for oncology, supported by a leadership team with a proven track record of advancing drugs to market.

Therapeutic Areas